Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Assaf Graif

Vascular & Interventional Radiology Newark, DE Medical Doctor

NPI 1598051781 CMS profile 71301

4755 Ogletown Stanton Road, Center For Heart & Vascular Health, Suite 1E20, Newark, DE 19718

Open in the dashboard

General payments

$82,616

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Assaf Graif of Newark, DE is reported in the CMS Open Payments database as having received $82,616 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $39,275 79
2024 General $30,522 73
2023 General $4,238 42
2022 General $6,596 34
2021 General $647 8
2020 General $102 5
2019 General $1,235 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Assaf Graif
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Assaf Graif were reported at $39,275. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Assaf Graif Vascular & Interventional Radiology median Middle half National median
2019 $1,235 $422 $125–$1,555 $163
2020 $102 $200 $68–$652 $114
2021 $647 $280 $99–$866 $132
2022 $6,596 $433 $137–$1,497 $149
2023 $4,238 $506 $152–$2,019 $160
2024 $30,522 $556 $175–$1,930 $164
2025 $39,275 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $69,189 175 payments
  2. Penumbra, Inc. $8,319 22 payments
  3. Bard Peripheral Vascular, Inc. $1,845 9 payments
  4. Balt USA, LLC $1,230 14 payments
  5. Inari Medical, Inc. $271 6 payments
  6. Neptune Medical Inc. $260 1 payment
  7. Sirtex Medical Inc $222 10 payments
  8. Cook Medical LLC $174 4 payments
  9. Ge Healthcare $173 1 payment
  10. Thrombolex, Inc. $141 1 payment
  11. Other $791 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,150 15 payments
  2. Consulting Fee $15,675 15 payments
  3. Food and Beverage $11,630 198 payments
  4. Travel and Lodging $11,161 40 payments
  5. Honoraria $1,000 2 payments
Products named General payments · program years 2019–2025
  1. General - Therapies $26,366 21 payments
  2. EkoSonic $24,727 47 payments
  3. Indigo System $8,012 19 payments
  4. Venous Wolf $4,620 5 payments
  5. General - Thrombectomy $3,929 7 payments
  6. General - Vascular Intervention $1,786 9 payments
  7. Wolf Trap $1,416 3 payments
  8. Arterial Wolf $788 2 payments
  9. Prestige Coil System $765 8 payments
  10. ELUVIA $607 13 payments
  11. Other $4,756 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

27

Median for Interventional Radiology: 38

Drug cost

$18,960

Median for Interventional Radiology: $333

Branded share of claims

100%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $18,786
Clopidogrel Clopidogrel Bisulfate Brand 12 $174

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 116 billing codes

Paid by Medicare

$84,167

Medicare's payments for the services billed

Medicare patients

602

Average age 74

Services billed

1,223

318 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 50%
Diabetes 47%
Ischemic heart disease 45%
Heart failure 38%
Depression 36%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record